Sign In
Buy HIMS
$27.77
+0.730 (+2.70%)
At Close: Jul 31, 2026
Why Hims & Hers Health, Inc. (HIMS) is a Top Growth Stock for the Long-Term
10:46am, Thursday, 23'rd Apr 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Hims & Hers expands into menopause care as estrogen patch demand rises
11:27am, Wednesday, 22'nd Apr 2026
Telehealth company Hims & Hers said on Wednesday it will now offer treatment options for perimenopause and menopause via its platform, as rising U.S. demand for hormone therapy strains supplies
Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors
06:46pm, Tuesday, 21'st Apr 2026
Hims & Hers Health, Inc. (HIMS) reached $29.76 at the closing of the latest trading day, reflecting a -4.03% change compared to its last close.
Stock Market Today, April 21: Hims & Hers Health Drops as Amazon Unveils Competing Weight Loss Program
04:59pm, Tuesday, 21'st Apr 2026
Expand NYSE: HIMS Hims & Hers Health Today's Change (-3.89%) $-1.21 Current Price $29.80 Key Data Points Market Cap $7.1B Day's Range $27.90 - $30.86 52wk Range $13.74 - $70.43 Volume 2.1M Avg Vol 38M
Did Amazon Just Wreck All of Hims & Hers Upside Potential?
12:04pm, Tuesday, 21'st Apr 2026
The GLP-1 weight-loss category exploded into a multi-billion-dollar opportunity that blends medication access with ongoing patient support.
Hims & Hers Builds Scalable Data-Driven Personalized Care Platform
11:50am, Tuesday, 21'st Apr 2026
HIMS is building a data-driven care platform, adding Labs and multi-cancer testing to personalize treatment via continuous monitoring insights.
Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 18,005 Shares
05:02am, Tuesday, 21'st Apr 2026
Hims and Hers Health, Inc. (NYSE: HIMS - Get Free Report) CFO Oluyemi Okupe sold 18,005 shares of the stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $27.8
Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal
10:40am, Monday, 20'th Apr 2026
Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors pile into the stock ahead of a May 11 earnings report.
What's Going On With Hims & Hers Shares
10:45am, Friday, 17'th Apr 2026
Earlier this week, the Food and Drug Administration said it plans to host a meeting in July to loosen regulations on peptides injections, which are compounded treatments that have increased in popular
Hims & Hers Health (HIMS) Soars 11.1%: Is Further Upside Left in the Stock?
07:27am, Friday, 17'th Apr 2026
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies
04:57pm, Thursday, 16'th Apr 2026
Expand NYSE: HIMS Hims & Hers Health Today's Change (11.28%) $2.74 Current Price $27.03 Key Data Points Market Cap $5.5B Day's Range $24.77 - $27.81 52wk Range $13.74 - $70.43 Volume 2.5M Avg Vol 35M
RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
01:44pm, Thursday, 16'th Apr 2026
Investors are starting to focus on what will replace compounded GLP-1 driven growth for telehealth companies like Hims & Hers Health. Peptides are gaining attention as a potential new growth vector, d
Hims & Hers shares jump as FDA begins review of restricted peptide compounds
01:14pm, Thursday, 16'th Apr 2026
Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug Administration (FDA) moved to begin a formal review process that could eventually reshape the regula
Hims rises as FDA considers broader peptides access; analysts see long-term win
11:34am, Thursday, 16'th Apr 2026
Shares of Hims & Hers Health rose more than 7% on Thursday as analysts said the U.S. drug regulator's consideration to allow compounding pharmacies to manufacture popular peptides could benefit the
HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell?
10:51am, Thursday, 16'th Apr 2026
Hims & Hers rolls out Benefits and taps Novo Nordisk for GLP therapies in weight-loss care as revenue grows, but margins and cash flow tighten.
